Neuronox® 100 Units | Medytox (Botulinum Toxin Type A)

Short Description

The pioneer of South Korean neuromodulator medicine, Neuronox® by Medytox is a globally established, clinically validated Botulinum Toxin Type A injectable. Engineered with a stable 900 kDa molecular complex, it provides precise dynamic wrinkle smoothing, reliable localized diffusion, and proven therapeutic performance for medical aesthetic clinics and dermatology specialists.

Detailed Description

Neuronox® (scientifically designated as Meditoxin in specific global markets) is South Korea’s first domestically developed botulinum toxin formulation, backed by nearly two decades of clinical use across more than 40 countries. Developed through advanced bio-fermentation and strict chromatographic isolation techniques, Neuronox delivers an ultra-consistent Clostridium botulinum type A neurotoxin complex bound to stabilizing non-toxic non-hemagglutinin proteins.

At the presynaptic neuromuscular junction, Neuronox cleaves the SNAP-25 protein, preventing acetylcholine vesicle fusion and neurotransmitter release. This targeted mechanism reduces hyperkinetic muscle contractility, smoothing expression rhytids and rebalancing dynamic facial muscle tone while maintaining natural expressive movement.

Treatment Areas & Indications

• Upper Facial Aesthetics:

  • Moderate-to-severe glabellar frown lines (Corrugator and Procerus complex)

  • Horizontal forehead lines (Frontalis muscle)

  • Lateral canthal rhytids (Crow’s feet / Orbicularis oculi)

• Lower Facial Contouring & Myomodulation:

  • Masseter muscle hypertrophy (V-line jaw contouring and bruxism relief)

  • Transverse nasal lines (Bunny lines)

  • Depressor Anguli Oris (DAO) treatment for downturned corners of the mouth

  • Mentalis hyperkinesis (Peau d’orange / chin dimpling)

  • Platysma muscle bands (Nefertiti neck lift)

• Clinical & Therapeutic Applications:

  • Severe primary focal axillary and palmar hyperhidrosis

  • Blepharospasm and facial hemispasm

Key Clinical Advantages

• Established 900 kDa Benchmark: Features the classic high-molecular-weight complex that delivers predictable, controlled diffusion with minimal lateral spread into adjacent musculature.

• Extensive Global Clinical Track Record: With clinical safety and efficacy data documented since its initial approval in 2006, it provides proven bioequivalence and therapeutic reliability.

• Predictable Dosage-to-Response Ratio: Facilitates smooth clinical translation and reproducible results across standard botulinum toxin injection protocols.

• Rapid Clinical Onset & Longevity: Initial muscle relaxation becomes apparent within 2 to 3 days, consolidating into peak aesthetic expression at 10 to 14 days, with results lasting between 4 to 6 months.

Technical Specifications

Professional Advisory: Neuronox® is a medical-grade pharmaceutical intended exclusively for licensed dermatologists, plastic surgeons, and accredited aesthetic medical practitioners. Not authorized for retail sale or direct consumer administration.